Pharming Group N.V. (PHAR)Healthcare | Biotechnology | Leiden, Netherlands | NasdaqGM
17.34 USD
-0.01
(-0.058%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 17.65 +0.31 (1.788%) ⇧ (April 17, 2026, 7:23 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:55 a.m. EDT
PHAR exhibits severe long-term value degradation evidenced by an astronomical 32.18 Target/Enterprise-to-Revenue gap and effectively zero cash flow yield (15%), rendering it a poor buy-and-hold candidate despite short-term bullish analyst sentiment; the lack of dividend history and deteriorating fundamentals suggest the bull case is priced in and relies heavily on future growth execution which faces significant Valuation Risk. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.233014 |
| AutoARIMA | 0.233212 |
| AutoTheta | 0.242293 |
| MSTL | 0.243214 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 50% |
| H-stat | 0.98 |
| Ljung-Box p | 0.001 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 5.12 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 41.781 |
| Revenue per Share | 5.46 |
| Market Cap | 1,224,641,536 |
| Trailing P/E | 433.50 |
| Forward P/E | 47.25 |
| Beta | 0.12 |
| Profit Margins | 0.76% |
| Website | https://www.pharming.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1276073 |
| Address1 | Darwinweg 24 |
| All Time High | 21.99 |
| All Time Low | 6.1 |
| Ask | 17.85 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 13,670 |
| Average Daily Volume3 Month | 26,659 |
| Average Volume | 26,659 |
| Average Volume10Days | 13,670 |
| Beta | 0.122 |
| Bid | 17.34 |
| Bid Size | 1 |
| Book Value | 0.418 |
| City | Leiden |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 17.34 |
| Current Ratio | 2.586 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 17.6846 |
| Day Low | 17.34 |
| Debt To Equity | 41.781 |
| Display Name | Pharming |
| Earnings Call Timestamp End | 1,746,703,800 |
| Earnings Call Timestamp Start | 1,746,703,800 |
| Earnings Growth | 1.042 |
| Earnings Quarterly Growth | 0.864 |
| Earnings Timestamp End | 1,753,938,000 |
| Earnings Timestamp Start | 1,753,938,000 |
| Ebitda | 39,615,000 |
| Ebitda Margins | 0.10532 |
| Enterprise To Ebitda | 305.536 |
| Enterprise To Revenue | 32.18 |
| Enterprise Value | 12,103,813,120 |
| Eps Current Year | 0.13633 |
| Eps Forward | 0.367 |
| Eps Trailing Twelve Months | 0.04 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 16.242 |
| Fifty Day Average Change | 1.0979996 |
| Fifty Day Average Change Percent | 0.067602485 |
| Fifty Two Week Change Percent | 112.760735 |
| Fifty Two Week High | 21.34 |
| Fifty Two Week High Change | -4.0 |
| Fifty Two Week High Change Percent | -0.18744142 |
| Fifty Two Week Low | 8.049 |
| Fifty Two Week Low Change | 9.291 |
| Fifty Two Week Low Change Percent | 1.154305 |
| Fifty Two Week Range | 8.049 - 21.34 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,608,733,800,000 |
| Float Shares | 690,783,343 |
| Forward Eps | 0.367 |
| Forward P E | 47.247955 |
| Free Cashflow | 68,654,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 407 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.87903 |
| Gross Profits | 330,633,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.00201 |
| Implied Shares Outstanding | 70,625,230 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-12-22 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. |
| Long Name | Pharming Group N.V. |
| Market | us_market |
| Market Cap | 1,224,641,536 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_32943 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 2,851,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,242,124,692 |
| Number Of Analyst Opinions | 4 |
| Open | 17.61 |
| Operating Cashflow | 54,708,000 |
| Operating Margins | 0.02843 |
| Payout Ratio | 0.0 |
| Phone | 31 71 524 7400 |
| Post Market Change | 0.30999947 |
| Post Market Change Percent | 1.7877709 |
| Post Market Price | 17.65 |
| Post Market Time | 1,776,468,213 |
| Previous Close | 17.35 |
| Price Eps Current Year | 127.19138 |
| Price Hint | 2 |
| Price To Book | 41.483253 |
| Price To Sales Trailing12 Months | 3.2558649 |
| Profit Margins | 0.00758 |
| Quick Ratio | 1.965 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0100002 |
| Regular Market Change Percent | -0.0576382 |
| Regular Market Day High | 17.6846 |
| Regular Market Day Low | 17.34 |
| Regular Market Day Range | 17.34 - 17.6846 |
| Regular Market Open | 17.61 |
| Regular Market Previous Close | 17.35 |
| Regular Market Price | 17.34 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 7,020 |
| Return On Assets | 0.045500003 |
| Return On Equity | 0.010190001 |
| Revenue Growth | 0.15 |
| Revenue Per Share | 5.46 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 70,625,230 |
| Shares Percent Shares Out | 0.0002 |
| Shares Short | 12,882 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 11,389 |
| Short Name | Pharming Group N.V. |
| Short Percent Of Float | 0.0002 |
| Short Ratio | 0.54 |
| Source Interval | 15 |
| Symbol | PHAR |
| Target High Price | 41.0 |
| Target Low Price | 23.4 |
| Target Mean Price | 34.6 |
| Target Median Price | 37.0 |
| Total Cash | 179,100,992 |
| Total Cash Per Share | 0.255 |
| Total Debt | 115,775,000 |
| Total Revenue | 376,134,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.04 |
| Trailing P E | 433.5 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.14871 |
| Two Hundred Day Average Change | 2.19129 |
| Two Hundred Day Average Change Percent | 0.1446519 |
| Type Disp | Equity |
| Volume | 7,020 |
| Website | https://www.pharming.com |
| Zip | 2,333 CR |